Literature DB >> 17666143

Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma.

S Cafer1, I Bayramoglu, N Uzum, M Yilmaz, L Memis, K Uygur.   

Abstract

OBJECTIVE: The objective was to assess the presence of Ki-67, and oestrogen and progesterone hormone receptors as well as their clinical correlates in acoustic neuroma.
METHODS: Medical records of 59 patients who were operated on for acoustic neuroma between 1995 and 2003 were evaluated retrospectively. Formaldehyde-fixed paraffin-embedded archival acoustic neuroma specimens of the patients were used for immunohistochemical assessments of oestrogen and progesterone hormone receptors, and Ki-67 proliferative marker.
RESULTS: Tumour sizes were small (40 mm) in 21, 35 and 3 patients, respectively. On immunohistochemistry, all samples were (+) for progesterone receptor and (-) for oestrogen receptor staining. Ki-67 staining was encountered in 34 of 59 (57.6 per cent) patients, and Ki-67 values ranged from 0 per cent to 10.9 per cent (mean 1.36 per cent). There was no correlation between Ki-67, gender, tumour size and symptoms of the patients (p > 0.05).
CONCLUSION: Oestrogen is not an important hormone in acoustic neuroma due to the absence of oestrogen receptor expression in the tissue samples. Since the progesterone receptor is expressed in all acoustic neuroma samples, further studies are necessary to find out about the inhibitory effect of antiprogesterone treatment on acoustic neuroma growth, which may be important particularly in elderly people or high-risk patients. Although Ki-67 is expressed in the majority of acoustic neuromas, it is not an important marker in clinical practice due to a lack of any correlation with the clinical parameters.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666143     DOI: 10.1017/S0022215107000229

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  9 in total

1.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

2.  Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.

Authors:  Andrew K Patel; Thomas H Alexander; Ali Andalibi; Allen F Ryan; Joni K Doherty
Journal:  Laryngoscope       Date:  2008-08       Impact factor: 3.325

3.  Incidence of vestibular schwannomas in the United States.

Authors:  Varun R Kshettry; Jason K Hsieh; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

4.  Intraosseous schwannoma of the petrous apex.

Authors:  Christopher Goiney; Rita Bhatia; Kevin Auerbach; Michael Norenberg; Jacques Morcos
Journal:  J Radiol Case Rep       Date:  2011-11-01

5.  Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.

Authors:  Aubrey L Park; Hsueh-Kung Lin; Qing Yang; Chor Wing Sing; Michael Fan; Timothy B Mapstone; Naina L Gross; Mary K Gumerlock; Michael D Martin; Craig H Rabb; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2010-03-25

6.  Management of large and giant vestibular schwannomas.

Authors:  Irumee Pai; James Bowman; Nick Thomas; Neil Kitchen; Anthony Strong; Rupert Obholzer; Michael Gleeson
Journal:  Skull Base       Date:  2011-11

7.  Expression of estrogen and progesterone receptors in vestibular schwannomas and their clinical significance.

Authors:  Sushila Jaiswal; Vinita Agrawal; Awadhesh Kumar Jaiswal; Rakesh Pandey; Ashok Kumar Mahapatra
Journal:  J Negat Results Biomed       Date:  2009-11-04

8.  Subtotal resection of vestibular schwannoma: Evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation.

Authors:  Giannicola Iannella; Marco de Vincentiis; Cira Di Gioia; Raffaella Carletti; Benedetta Pasquariello; Alessandra Manno; Diletta Angeletti; Ersilia Savastano; Giuseppe Magliulo
Journal:  J Int Med Res       Date:  2017-04-27       Impact factor: 1.671

9.  Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.

Authors:  Jessica E Sagers; Adam S Brown; Sasa Vasilijic; Rebecca M Lewis; Mehmet I Sahin; Lukas D Landegger; Roy H Perlis; Isaac S Kohane; D Bradley Welling; Chirag J Patel; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.